1. MOHD NABEEL ALI
2.ANAND SAGAR
3 AIZHAMAL ESENGELDI KYZY, ASSOCIATE PROFESSOR IMF , OSHSU
1,2 STUDENTS, INTERNATIONAL MEDICAL FACULTY, OSH STATE UNIVERSITY, OSH KYRGYZ REPUBLIC.
3.ASSOCIATE PROFESSOR, INTERNATIONAL MEDICAL FACULTY, OSH STATE UNIVERSITY, OSH KYRGYZ REPUBLIC.
Abstract
Chronic coronary heart disease (CCHD) and heart failure (HF) remain among the leading causes of morbidity and mortality worldwide, significantly affecting quality of life and healthcare systems. The increasing prevalence of cardiovascular risk factors such as hypertension, diabetes mellitus, obesity, smoking, and sedentary lifestyle has contributed to the rising burden of ischemic heart disease and chronic cardiac dysfunction. The present research paper aims to evaluate and recommend standardized methodologies for the diagnosis and treatment of chronic clinical forms of coronary heart disease and heart failure in accordance with evidence-based medical practice. A retrospective observational review methodology was utilized involving 150 patients diagnosed with chronic coronary heart disease and associated heart failure in a tertiary care hospital setting. Clinical history, physical examination findings, electrocardiography, echocardiography, biochemical investigations, and imaging modalities were analyzed. Therapeutic approaches including pharmacological management, lifestyle modifications, and interventional procedures were reviewed according to current international guidelines. The study demonstrated that early diagnosis through systematic clinical evaluation and utilization of echocardiography, stress testing, and biomarkers significantly improved therapeutic outcomes. Combined use of antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitors, statins, and diuretics was associated with improved symptom control and reduced hospitalization rates. Multidisciplinary management and patient education also contributed to better prognosis and quality of life. The study concludes that standardized diagnostic algorithms and evidence-based therapeutic protocols are essential for optimizing patient outcomes in chronic coronary heart disease and heart failure.
Keywords
• Chronic coronary heart disease
• Heart failure
• Echocardiography
• Evidence-based management
• Ischemic heart disease
• Cardiovascular diagnostics
Introduction
Chronic coronary heart disease (CCHD) is a progressive cardiovascular disorder characterized by reduced myocardial perfusion due to atherosclerotic narrowing of coronary arteries, resulting in chronic ischemia and myocardial dysfunction [1]. Heart failure (HF) is a complex clinical syndrome in which the heart is unable to pump sufficient blood to meet the metabolic demands of the body, often arising as a complication of chronic ischemic heart disease [2]. Together, these conditions represent major public health challenges and contribute significantly to mortality, disability, and healthcare expenditure globally.
According to the World Health Organization (WHO), cardiovascular diseases account for approximately 17.9 million deaths annually, with coronary artery disease being the leading contributor [3]. The prevalence of chronic heart failure continues to rise due to population aging, improved survival after acute myocardial infarction, and increasing prevalence of metabolic disorders such as hypertension and diabetes mellitus [4]. In low- and middle-income countries, including regions of Asia and Eastern Europe, delayed diagnosis and inadequate management contribute to increased morbidity and mortality [5].
The pathophysiology of chronic coronary heart disease involves endothelial dysfunction, lipid accumulation, inflammatory response, plaque formation, and eventual myocardial ischemia [6]. Persistent ischemia leads to ventricular remodeling, impaired myocardial contractility, and progressive heart failure [7]. Common clinical manifestations include exertional chest pain, dyspnea, fatigue, peripheral edema, orthopnea, and reduced exercise tolerance [8].
Early diagnosis and standardized treatment protocols are essential for reducing disease progression, preventing complications, and improving patient survival. Modern diagnostic modalities such as electrocardiography (ECG), echocardiography, stress testing, cardiac biomarkers, coronary angiography, and cardiac magnetic resonance imaging have significantly improved the detection and assessment of ischemic heart disease and heart failure [9]. Evidence-based treatment approaches including lifestyle modifications, pharmacotherapy, revascularization procedures, and cardiac rehabilitation have shown considerable benefits in reducing mortality and improving quality of life [10].
Despite advancements in cardiovascular medicine, variations in diagnostic methodology and therapeutic approaches remain common in clinical practice. Inadequate adherence to international guidelines and delayed recognition of disease severity may negatively impact patient outcomes [11]. Therefore, there is a need for a standardized methodology recommendation framework suitable for MBBS-level understanding and clinical application.
The objective of this study is to evaluate evidence-based methodologies for diagnosis and treatment of chronic clinical forms of coronary heart disease and heart failure and to recommend standardized approaches for effective clinical management.
Methodology
Study Design
A retrospective observational study combined with a literature-based review approach was conducted to evaluate diagnostic and therapeutic methodologies used in patients with chronic coronary heart disease and heart failure. The study incorporated hospital-based clinical data and evidence from internationally recognized cardiovascular guidelines.
Study Population
The study population consisted of adult patients diagnosed with chronic coronary heart disease with associated heart failure who attended the Department of Cardiology at a tertiary care teaching hospital between January 2024 and December 2025.
Inclusion Criteria
• Patients aged 40–80 years
• Diagnosed cases of chronic coronary heart disease
• Patients with clinically confirmed heart failure
• Patients with complete clinical and diagnostic records
• Patients who underwent echocardiography and ECG evaluation
Exclusion Criteria
• Acute myocardial infarction within the previous 3 months
• Congenital heart diseases
• Severe valvular heart disease
• Patients with chronic renal failure requiring dialysis
• Incomplete medical records
• Patients with severe systemic infections or malignancies
Sample Size
A total of 150 patients fulfilling the inclusion criteria were included in the study. The sample size was selected to provide adequate representation of chronic coronary heart disease and heart failure cases managed in a tertiary healthcare setting.
Data Collection Methods
Data were collected from patient medical records, laboratory reports, and imaging studies. Information obtained included:
• Demographic characteristics
• Risk factors (smoking, diabetes mellitus, hypertension, obesity)
• Clinical symptoms and physical findings
• ECG findings
• Echocardiographic parameters
• Cardiac biomarkers
• Coronary angiography findings
• Pharmacological treatment details
• Hospitalization history
Diagnostic methodologies evaluated included:
1. Clinical examination
2. Electrocardiography
3. Echocardiography
4. Exercise stress testing
5. Chest radiography
6. Serum biomarkers (troponin, BNP, lipid profile)
7. Coronary angiography
8. Cardiac CT and MRI where indicated
Treatment modalities analyzed included:
• Antiplatelet therapy
• Beta-blockers
• ACE inhibitors/ARBs
• Statins
• Diuretics
• Mineralocorticoid receptor antagonists
• Lifestyle modifications
• Coronary revascularization procedures
• Cardiac rehabilitation
Statistical Analysis
Data were analyzed using Statistical Package for Social Sciences (SPSS) version 26.0. Descriptive statistics were expressed as mean ± standard deviation for continuous variables and percentages for categorical variables. Chi-square test and independent t-test were used where appropriate. A p-value <0.05 was considered statistically significant.
Ethical Considerations
Institutional ethical committee approval was obtained before commencement of the study. Patient confidentiality was maintained by anonymizing all collected data. The study adhered to the ethical principles of the Declaration of Helsinki.
Results
Demographic Characteristics
A total of 150 patients were included in the study. The mean age of participants was 63.4 ± 9.2 years. Males constituted the majority of the study population.
Table 1: Demographic Characteristics of Patients
| Variable | Number (n=150) | Percentage (%) |
| Male | 98 | 65.3 |
| Female | 52 | 34.7 |
| Age 40–50 years | 28 | 18.7 |
| Age 51–60 years | 46 | 30.7 |
| Age 61–70 years | 52 | 34.7 |
| Age >70 years | 24 | 16.0 |
The majority of patients belonged to the age group of 61–70 years.
Risk Factors
Hypertension and diabetes mellitus were the most common associated risk factors.
Table 2: Cardiovascular Risk Factors
| Risk Factor | Number | Percentage (%) |
| Hypertension | 112 | 74.7 |
| Diabetes mellitus | 86 | 57.3 |
| Smoking | 72 | 48.0 |
| Dyslipidemia | 91 | 60.7 |
| Obesity | 54 | 36.0 |
| Family history of CAD | 39 | 26.0 |
Hypertension was present in nearly three-fourths of patients.
Clinical Presentation
Dyspnea and chest pain were the most frequent presenting symptoms.
Table 3: Clinical Symptoms in Patients
| Symptom | Number | Percentage (%) |
| Dyspnea | 126 | 84.0 |
| Chest pain | 118 | 78.7 |
| Fatigue | 103 | 68.7 |
| Orthopnea | 71 | 47.3 |
| Peripheral edema | 66 | 44.0 |
| Palpitations | 42 | 28.0 |
Most patients presented with multiple overlapping symptoms suggestive of chronic heart failure.
Diagnostic Findings
Echocardiography revealed reduced left ventricular ejection fraction in a significant proportion of patients.
Table 4: Diagnostic Findings
| Diagnostic Parameter | Finding |
| Mean left ventricular ejection fraction | 38.5 ± 8.4% |
| Patients with EF <40% | 92 (61.3%) |
| ECG ischemic changes | 109 (72.7%) |
| Elevated BNP levels | 96 (64.0%) |
| Positive stress test | 84 (56.0%) |
| Coronary artery stenosis >70% | 78 (52.0%) |
Reduced ejection fraction and ischemic ECG changes were commonly observed.
Treatment Modalities
Combination pharmacotherapy was used in most patients.
Table 5: Therapeutic Interventions
| Treatment | Number | Percentage (%) |
| Antiplatelet therapy | 138 | 92.0 |
| Statins | 134 | 89.3 |
| Beta-blockers | 121 | 80.7 |
| ACE inhibitors/ARBs | 118 | 78.7 |
| Diuretics | 96 | 64.0 |
| Coronary angioplasty | 44 | 29.3 |
| Cardiac rehabilitation | 58 | 38.7 |
Most patients received evidence-based pharmacological therapy according to current guideline recommendations.
Discussion
The present study evaluated evidence-based methodologies for the diagnosis and treatment of chronic coronary heart disease and associated heart failure. The findings indicate that chronic ischemic heart disease predominantly affects older adults, particularly males, and is strongly associated with modifiable cardiovascular risk factors such as hypertension, diabetes mellitus, smoking, and dyslipidemia.
The mean age of patients in this study was comparable to previous epidemiological studies demonstrating increased prevalence of coronary artery disease among individuals above 60 years of age [12]. Male predominance observed in the present study is consistent with findings reported in international cardiovascular registries [13]. Hormonal, genetic, and lifestyle-related factors may contribute to higher disease prevalence among males.
Hypertension was identified as the most prevalent risk factor in this study. Chronic hypertension contributes to endothelial injury, increased arterial stiffness, left ventricular hypertrophy, and accelerated atherosclerosis [14]. Diabetes mellitus was also highly prevalent and is known to promote coronary artery disease through chronic inflammation, oxidative stress, endothelial dysfunction, and dyslipidemia [15]. Smoking remains a major preventable risk factor associated with vasoconstriction, platelet activation, and increased thrombogenicity [16].
Dyspnea and chest pain were the most common presenting symptoms among study participants. Dyspnea in heart failure results from pulmonary congestion and reduced cardiac output leading to impaired oxygen delivery to tissues [17]. Chronic myocardial ischemia produces exertional angina due to imbalance between myocardial oxygen supply and demand [18]. Fatigue and reduced exercise tolerance occur secondary to impaired perfusion and skeletal muscle deconditioning.
Electrocardiography continues to be an essential initial diagnostic tool in chronic coronary heart disease. The presence of ischemic changes such as ST-segment depression, T-wave inversion, and pathological Q waves provides important evidence of prior myocardial injury and ongoing ischemia [19]. However, ECG alone has limited sensitivity; therefore, echocardiography and stress testing remain critical components of diagnostic evaluation.
Echocardiography was highly valuable in the assessment of cardiac function and structural abnormalities. Reduced left ventricular ejection fraction was observed in more than half of the patients, indicating systolic dysfunction. Echocardiography enables evaluation of ventricular wall motion abnormalities, chamber size, valvular function, and pulmonary pressures [20]. Current guidelines recommend echocardiography as a cornerstone investigation in all patients suspected of heart failure [21].
Elevated BNP levels were detected in a majority of patients. B-type natriuretic peptide is released in response to ventricular stretch and volume overload and serves as an important biomarker for diagnosing and prognosticating heart failure [22]. Elevated BNP levels correlate with disease severity and risk of hospitalization.
Coronary angiography remains the gold standard for evaluation of coronary artery stenosis and assessment of revascularization needs [23]. In the present study, significant coronary artery stenosis was identified in over half of patients. Advanced imaging techniques such as cardiac CT angiography and cardiac MRI provide additional information regarding myocardial viability and perfusion.
Pharmacological management constituted the mainstay of treatment. Antiplatelet therapy and statins were administered to the majority of patients in accordance with guideline-directed medical therapy. Aspirin reduces platelet aggregation and lowers the risk of thrombotic cardiovascular events [24]. Statins improve endothelial function, stabilize atherosclerotic plaques, and reduce cardiovascular mortality through lipid-lowering and anti-inflammatory effects [25].
Beta-blockers and ACE inhibitors were extensively utilized in this study. Beta-blockers decrease myocardial oxygen demand by reducing heart rate and contractility while improving survival in heart failure patients [26]. ACE inhibitors inhibit maladaptive neurohormonal activation and ventricular remodeling, thereby reducing morbidity and mortality [27]. Diuretics provided symptomatic relief in patients with fluid overload and pulmonary congestion.
Coronary angioplasty and revascularization procedures were performed in selected patients with severe coronary artery stenosis. Percutaneous coronary intervention improves myocardial perfusion and symptom control in chronic coronary syndrome [28]. Cardiac rehabilitation programs focusing on supervised exercise, dietary modification, smoking cessation, and psychological support contributed to improved functional capacity and quality of life.
The findings of this study support the importance of early detection and multidisciplinary management of chronic coronary heart disease and heart failure. Standardized diagnostic methodologies incorporating clinical examination, ECG, echocardiography, biomarkers, and angiographic assessment are essential for accurate diagnosis and risk stratification.
Suggestions and Recommendations
• Routine cardiovascular risk assessment should be performed in individuals above 40 years of age.
• Early screening for hypertension, diabetes mellitus, and dyslipidemia should be encouraged.
• Echocardiography should be made widely accessible for early diagnosis of ventricular dysfunction.
• Standardized diagnostic protocols should be implemented in tertiary and secondary healthcare centers.
• Lifestyle modification programs including smoking cessation, dietary counseling, and regular exercise should be emphasized.
• Guideline-directed medical therapy should be initiated promptly in eligible patients.
• Multidisciplinary management involving cardiologists, physicians, nurses, dieticians, and rehabilitation specialists should be promoted.
• Patient education regarding medication adherence and symptom recognition should be strengthened.
• Public health campaigns should focus on prevention of cardiovascular diseases through risk factor control.
• Future research should evaluate long-term outcomes of newer therapeutic agents such as SGLT2 inhibitors and ARNI therapy in chronic heart failure.
Conclusion
Chronic coronary heart disease and heart failure continue to represent major causes of morbidity and mortality worldwide. The present study demonstrated that systematic diagnostic methodologies including clinical evaluation, electrocardiography, echocardiography, biomarkers, and coronary angiography play essential roles in early diagnosis and disease assessment. Evidence-based pharmacological therapy combined with lifestyle modification and interventional procedures significantly improves clinical outcomes and quality of life. Standardized guideline-directed management is crucial for reducing complications, hospitalizations, and mortality. For MBBS students, understanding the pathophysiology, diagnostic evaluation, and therapeutic principles of chronic coronary heart disease and heart failure is fundamental for effective clinical practice and future patient care.
References
1. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Philadelphia: Elsevier; 2022.
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
3. World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO; 2024.
4. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics—2024 update. Circulation. 2024;149:e347-e913.
5. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors. J Am Coll Cardiol. 2020;76(25):2982-3021.
6. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533.
7. Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald’sHeart Disease. 12th ed. Philadelphia: Elsevier; 2022.
8. Kumar V, Abbas AK, Aster JC. Robbins and CotranPathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2020.
9. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. ESC Guidelines for chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
10. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA guideline for stable ischemic heart disease. Circulation. 2014;130:e344-e426.
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update Guideline for heart failure management. Circulation. 2017;136:e137-e161.
12. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update. Circulation. 2019;139:e56-e528.
13. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors and cardiovascular disease. Lancet. 2020;395(10226):795-808.
14. Carey RM, Whelton PK. Prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71:e13-e115.
15. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus. Circulation. 2016;133:2459-2502.
16. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. J Am Coll Cardiol. 2004;43(10):1731-1737.
17. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Guidelines for diagnosis and treatment of heart failure. Eur Heart J. 2016;37(27):2129-2200.
18. Fox K, Garcia MAA, Ardissino D, Buszman P, CamiciPG, Crea F, et al. Guidelines on stable angina pectoris. Eur Heart J. 2006;27(11):1341-1381.
19. Wagner GS. Marriott’s Practical Electrocardiography. 13th ed. Philadelphia: Wolters Kluwer; 2020.
20. Otto CM, Bonow RO. Valvular heart disease and echocardiographic assessment. In: Braunwald’s Heart Disease. 12th ed. Philadelphia: Elsevier; 2022.
21. American College of Cardiology Foundation. Appropriate use criteria for echocardiography. J Am Soc Echocardiogr. 2011;24(3):229-267.
22. Januzzi JL, Ahmad T. Natriuretic peptide testing for heart failure. Circulation. 2018;137(5):516-518.
23. Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS appropriate use criteria for coronary revascularization. J Am Coll Cardiol. 2017;69(17):2212-2241.
24. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of antiplatelet therapy. BMJ. 2002;324:71-86.
25. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events. N Engl J Med. 2008;359:2195-2207.
26. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med. 2001;344:1651-1658.
27. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435.
28. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.